The phosphodiesterase (PDE) 4 is the predominant cyclic AMP degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes. In addition, this enzyme is expressed in non-immune cells such as keratinocytes and fibroblasts. Highly selective PDE4 inhibitors are currently under evaluation for the treatment of asthma and/or chronic obstructive pulmonary disease. Due to the broad anti-inflammatory/immunomodulatory action of PDE4 inhibitors, it has been proposed that PDE4 inhibitors might also be efficacious for skin disorders such as atopic dermatitis. Consequently, PDE4 inhibitors including cilomilast and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation. These PDE4 inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis in mice, in the arachidonic acid induced skin inflammation in mice and in ovalbumin sensitised guinea pigs. The determination of cytokines in skin homogenates revealed that both Th1 as well as Th2 cytokines are suppressed by PDE4 inhibitors, indicating an anti-inflammatory activity in both the Th2 dominated acute phase as well as the Th1 dominated chronic phase of atopic dermatitis. Due to the suppression of Th1 cytokines, activity can also be expected in psoriasis.
INTRODUCTION
Phosphodiesterases play a pivotal role in degrading cyclic nucleotides (cGMP, cAMP), key second messengers in all cells. Particularly cAMP plays an important regulatory role in virtually all the cell types involved in the pathophysiology of allergic and inflammatory diseases including asthma and chronic obstructive pulmonary disease, but also skin diseases including atopic dermatitis and psoriasis. Of the cAMP-degrading PDEs, PDE4 is the one that has been studied most extensively in recent years. PDE4 is abundant, and is the major cAMP-degrading isoenzyme in almost all inflammatory and immune cells. In spite of varied structural classes, highly selective PDE4 inhibitors have the same quality in suppressing several pro-inflammatory mechanisms like cytokine generation and secretion, superoxide generation, degranulation, IgE production, proliferation, histamine generation and chemotaxis [1] [2] [3] .
The PDE4 family comprises four genetically distinct subtypes (PDE4 A-D). These subtypes differ with respect to their regulatory behaviour and tissue expression patterns. Recent findings suggest that PDE4D may be responsible for the pro-emetic effect of PDE4 inhibitors [4, 5] . Furthermore, there are indications that LPS-induced TNF release from *Address correspondence to this author at the Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Foundation, D-30559 Hannover, Germany; Tel: ++49 (0)511 9538732; Fax: ++49 (0)511 9538581, E-mail: wolfgang.baeumer@tiho-hannover.de human monocytes and T-cell proliferation are closely correlated with inhibition of PDE4A and/or PDE4B, whereas no such correlation has been found with PDE4D-selective compounds (6) . However, studies using PDE4B and PDE4D knock out mice demonstrated that PDE4B and PDE4D play complementary roles in the regulation of neutrophil function [7] . More advanced understanding of PDE4 heterogeneity reveals that individual isoforms generated by the four PDE4 families (nearly 20 subfamilies are known to date) confer isoform-specific targeting to distinct intracellular sites and signalling complexes. A detailed review of this compartmentalisation of cAMP signalling is given by Houslay et al. (2005) [3] .
There is a structural diversity of PDE4 inhibitor families (Fig. 1) . The xanthine derivative theophylline is a weak and nonselective PDE inhibitor. More PDE4 selective, but not highly selective xanthine derivatives include arofylline (1) and cipamfylline (2) . Rolipram (3) is the archetype of the catechol class of PDE4 inhibitors. Cilomilast (5) and roflumilast are the most advanced representatives of this class. Atizoram (6) , also member of this class, has been tested for the treatment of atopic dermatitis. New chemical classes have been developed, such as the indole derivative AWD 12-281 (7) or the thalidomide derivative CC-10004 (8) .
The reported PDE4 selectivity of several PDE4 inhibitors mentioned in this review are summarised in Table 1 .
The efficacy of PDE4 inhibitors in animal models of asthma and COPD is well documented. The most clinically advanced PDE4 inhibitors cilomilast and roflumilast completed phase III studies for COPD and roflumilast also for asthma [11] . However, Altana has withdrawn the EU Marketing Authorisation Application for roflumilast (Daxas ® ). But Altana "is committed to continue the development of roflumilast and will pursue further clinical studies to strengthen the anti-inflammatory product profile and possible market potential of Daxas ® " (press release 15th November 2005 (http://www.altana.de/root/index.php?page_ id=202& cms_press_id=377)). This review focuses on the potential of highly selective PDE4 inhibitors for the treatment of skin disorders including atopic dermatitis and psoriasis. Several preclinical and some clinical studies have been performed, which clearly demonstrate efficacy in both animal models and small clinical trials. Fig. 2 provides a schematic overview of an allergic skin disease and its modulation by PDE4 inhibitors. Fig. (1) . PDE4 inhibitors for which preclinical or clinical data for the treatment of skin disorders are obtainable. The chemical structures display the diversity of PDE4 inhibitor families including xanthine derivatives (1, 2), catechol derivatives (3-6) and an indole derivate (7) . For the thalidomide derivate CC-10004, the structure has not been released, yet. This proposed structure is taken from [10] . C represents different possibilities for the side chain Z, see [10] for details.
ATOPIC DERMATITIS AND PSORIASIS: MARKET ENVIRONMENT
Psoriasis and atopic dermatitis, both being diseases with high prevalence and differ considerably in their disease profile with regard to new treatment options. Therefore, they will be discussed separately.
Atopic Dermatitis
Atopic dermatitis, or allergic eczema, is defined as a chronic, pruritic, superficial inflammation of the skin [12] . Patients with atopic dermatitis often have a familial history of allergic disorders and these patients also have a significantly higher risk to develop allergic rhinitis or asthma later in life. Atopic dermatitis is most often characterised by dry, red, extremely itchy areas of inflammation, commonly in the folds of the elbows or knees. Swelling, cracking, weeping, crusting and scaling of affected areas may occur. Atopic dermatitis is usually a chronic condition that cycles through periods of remission and flare. In chronic atopic dermatitis, the irritable area is often darker than the surrounding skin and may be lichenified, due to scratching. Spontaneous remission is frequent and only a small percentage of patients afflicted with atopic dermatitis during early life suffering from chronic AD later in life [12] .
The over all prevalence of atopic dermatitis is in the range of 1-3 percent in adults while the prevalence is much higher in children [13] . According to Akdis et al. (2006) , in * Partially purified PDE enzyme preparations derived from human monocytes/eosinophils. The data vary due to different experimental settings such as substrate concentration, source and purification of PDE4 (see references for details).
Fig. (2)
. Schematic presentation of an allergic skin disease and its modulation by PDE4 inhibitors. PDE4 inhibitors modulate several aspects of the allergic/inflammatory process. The migration of skin dendritic cells is inhibited and this inhibition is accompanied by an inhibition of MMP-9 activity in epidermis and dermis [31, 33] . Cytokine secretion (TNF , IL-1 and IL-12) of dendritic cells is impaired in human and murine dendritic cells by PDE4 inhibitors [31] [32] [33] An inhibition of T cell activation is also demonstrated in vitro [33, 49, 50] . Both Th1 and Th2 cytokines are reduced by PDE4 inhibitors in vitro [36, 49, 50] and in inflamed murine skin [29, 36] . The secretion of proinflammatory mediators by activated keratinocytes is also affected by PDE4 inhibition [34] . Thus, there is a reduced secretion of chemotactic factors for subsequent inflammatory cell influx (macrophages, T cells, neutrophil granulocytes) which results in a diminished inflammatory response in allergic skin diseases [21, 27, 29, 30] . KC= keratinocyte, LC = Langerhans cell, Mph = macrophage, N= neutrophil granulocyte, T = T cell. X = inhibition by PDE4 inhibitors.
developed countries, approximately 10-15% of children younger than five years of age have atopic dermatitis, of whom 45% present with signs in the first six months of life [12] .
The market size for atopic dermatitis is comparable to the market of psoriasis (q.v.). A rapid market growth can be attributed both to the introduction of two new compounds and to the growing prevalence of atopic dermatitis in developed countries.
Treatment of atopic dermatitis is symptomatic and involves pharmacological and non-pharmacological approaches. Skin hydration, emollients, anti-histamines and topical corticosteroids have traditionally been used to reduce the itching and to break the cycle of itching and scratching which often aggravates the symptoms [12] . But treatment is generally considered un-satisfactory, since the commonly prescribed drugs have limited efficacy and/or have unacceptable side effects. The side effect problem in atopic dermatitis is even more serious than in other skin diseases since the majority of patients (>60%) are below 2 years of age [12] . In this population, the use of corticosteroids is perceived as being problematic. Systemic corticosteroids, cyclosporine and phototherapy are used in severe, refractory cases but the side effect profile is clearly not acceptable. In recent years, a new class of drugs has reached the market. These so called topical immune modulating agents (TIM), the calcineurin inhibitors tacrolimus and pimecrolimus were promised to have a better side effect profile than topical corticosteroids while maintaining their efficacy. But efficacy was found to be inferior to steroids and the side effect profile, while different from corticosteroids, will require close monitoring over the long term. A black box warning that TIMs may facilitate skin cancer is an indication that tolerability may be limited. However, both the American Academy of Allergy, Asthma and Immunology and the European Dermatology Forum state that current data do not support black box warning on topical pimecrolimus and tacrolimus [14, 15] . Nevertheless, to date both marketed TIMs are only registered for use in children above the age of 2, which excludes a large percentage of patients from treatment. Thus, both drugs failed to meet the target profile of an ideal atopic dermatitis drug. Nevertheless, annual worldwide sales were greater than 100 million USD for each of the compounds [16] .
Rapid double digit growth in sales for these drugs indicates that there is a high demand for effective and highly tolerated drugs for this indication. Future development projects are aiming to meet these needs. In contrast to psoriasis, the focus is on topical treatment and topical PDE4 inhibitors are likely to deliver a treatment with a superior safety profile as compared to the TIMs. One such development project is AWD 12-281, which is in co-development between GSK and elbion AG. In addition, oral immune suppressants such as ISA247 will find their way into the market filling the niche of severe atopic dermatitis.
Psoriasis
Psoriasis is a chronic disorder that remits and relapses over time. Factors that may exacerbate psoriasis or cause the disease to recur include trauma, infection, stress and certain drugs such as beta receptor blockers. The extent of psoriasis varies and tends to fluctuate, even without treatment. The condition sometimes even disappears completely. A predisposition to develop psoriasis remains however in this case. Psoriasis is a relatively common condition, affecting 1-3% of the world's population. Currently up to 19 million people suffer from psoriasis in the 7 major pharmaceutical markets, with the US accounting for the largest proportion of these patients. The prevalence of psoriasis in Japan and also in East-Asians is low. Psoriasis is virtually non-existent in ethnic groups native to North and South America. This indicates, that these populations including the Inuit may not be genetically pre-disposed, supporting the role of genetic factors for the pathogenesis of psoriasis. However, dietary and geographic influence factors have been identified as well. Some studies have found that psoriasis develops earlier and more frequently in colder climates, such as in northern Europe. Psoriasis occurs more frequently in African Americans and Caucasians who live in colder climates than in people of any ethnicity who life in Africa indicating that natural sunlight (as well as UV radiation) can have a positive effect on psoriasis [16] .
Psoriasis is not a homogenous disease. Indeed, 5 different forms can be clinically differentiated. Plaque psoriasis is the most common form, and is characterised by well-defined patches of red, raised skin. Around 80% of psoriasis patients suffer from plaque psoriasis. The other main types of psoriasis differ with regard to the type of skin changes, the involvement of skin thickening and the occurrence of pustulae. Other differentiating factors are age or onset of the disease and the occurrence of special human leukocyte antigens (HLA). Type I psoriasis has an early onset (during adolescence and young adulthood) with a prevalence for a certain HLA allele and a familiar segregation. This type of psoriasis generally has a relatively severe disease course. Type II psoriasis shows no familiar segregation and different HLA markers. The onset is often seen around the age of 40 indicating a late onset and the severity is generally mild. While psoriasis mainly effects the skin, systemic components of the disease are well known affecting mostly the joints but also other tissues. Depending on the source, 10-30% of psoriasis patients are reported to have psoriatic arthritis, amounting to a prevalence of 0.5% of psoriasis arthritis in the US population [16] . Psoriasis is not a lethal disease and as many as 50% of US patients are not seeking medical assistance. However, more severe psoriasis attacks and even more so psoriasis arthritis can have severe impact on live and individual performance.
Psoriasis comprises a large and very rapidly growing market. While in 2003 the global sales for psoriasis drugs totalled 635 million USD, the marketing of the most recently registered, and upcoming biologics resulted nearly in a doubling of the market size. Each of the individual biologics are expected to generate peak annual sales above 400 million USD [16] .
As psoriasis in most cases is a life-long condition, treatments are expected to be not only safe, but also convenient to use. An ultimate goal is to achieve periods of remission where no treatment is needed. These needs are not fulfilled by currently marketed drugs. Emollients to be administered topically are often well tolerated but lack efficacy and convenience of use. Emollients with better treatment effects such as steroids are less well tolerated and steroid induced side effects are not well accepted. Compounds which can be administered orally include vitamin A and D derivatives and immune suppressants. Especially with regard to the immune suppressants, the clinical efficacy is very high, limited by their low tolerability.
Beginning in 2003, biologics with activity in psoriasis have reached the market and more compounds are in the pipeline. While these compounds including alefacept (LFA-3/IgG 1 fusion protein, binds to CD2 of activated T-cells), efalizumab (humanised antibody that binds to CD11a on Tcells), etanercept (TNF receptor fusion protein) and infliximab (chimeric monoclonal antibody against TNF ) retain the high efficacy of immunosuppressants such as cyclosporine, they differ in side effect profile. Indeed, the safety profile known to date is very positive, but due to the nature of the compounds, i.e. antibodies or human fusion proteins, and due to their targets, i.e. the immune system, the long term tolerability is still unknown for each individual product (see [17] for review). Also, the ease of use and the disruption of daily life is to be taken into account for evaluation of the compounds. While a s.c. self-injection may not be possible for every patient, a weekly intramuscular injection or even an intravenous infusion can be disruptive.
Late additions to the portfolio of anti-psoriasis drugs under development are the cyclosporine derivative ISA247 (R1524) under co-development between Roche and Isotechnika and the PDE4 inhibitor CC-10004 (Celgene corporation), both aiming at oral treatment of psoriasis [10, 18] . ISA247 is reported to retain the efficacy of cyclosporine while having a better side effect profile. This profile makes the compound a very promising candidate, especially in view of the highly priced biological competitors [18] . The clinical profile of PDE4 inhibitors is not yet clear. The first clinical data for CC-10004 indicates that efficacy may be low while the side effect profile, though different from cyclosporine, remains to be completely defined and may not be satisfactory.
Although the treatment of psoriatic arthritis requires a systemically administered compound such as CC-10004 and ISA247, there is clearly also a need for highly effective and easy to use topical treatments which show a better safety profile compared to topical steroids. This need may be filled with PDE4 inhibitors optimised for topical administration.
PRECLINICAL MODELS

Rolipram (3)
The first generation PDE4 inhibitor, rolipram has primary been evaluated in clinical trials for its antidepressant activity. The dose limiting side effects like nausea, vomiting and gastric acid production resulted in discontinuing its development. Rolipram is still a reference compound for in vitro testing of new PDE4 inhibitors and much data have been obtained from animal models of asthma and chronic obstructive pulmonary disease [2] . Early studies have also been performed for possible dermatological applications. Rolipram has been tested in an irritative rat ear oedema model. Topically administered rolipram (0.015-1.5 mg) inhibited the croton oil induced ear oedema formation by up to 80% and the effect was dose dependent [19] . Systemically administered rolipram inhibited eosinophil accumulation in a guinea pig model of passive cutaneous anaphylaxis and models of mediator induced eosinophilia, but oedema formation and neutrophil accumulation was mostly unaffected [20] .
In a recently published report, orally administered rolipram was tested in a chronic allergic dermatitis model induced by repeated epicutaneous exposure to the hapten trinitrochlorobenzene (TNCB). Rolipram (1-10 mg/kg) inhibited the TNCB induced ear swelling and reduced IL-1 , IL-4, IL-6 as well as IL-18 in inflamed ear skin in a dose dependent manner. In contrast to cyclosporine A and prednisolone, rolipram failed to reduce the draining lymph node cell numbers. However, only draining lymph node cells from rolipram treated mice showed reduced IL-4 secretion after ex vivo stimulation with anti-CD3 antibody [21] . Topically administered rolipram was also tested in a small clinical trial (see results from clinical studies).
Piclamilast (RPR 73401) (4)
Piclamilast was successfully tested in models of asthma and rheumatoid arthritis. Clinical trials for the treatment of these two diseases, however, were unimpressive and led to its discontinuation [2] . Piclamilast was also tested in two models of allergic contact dermatitis induced by the haptens dinitrochlorobenzene (DNCB) and toluenediisocyanate (TDI). Following challenge with these haptens, a reduction in ear thickness was achieved by dosing with either topically (3%) or intraperitoneally (1 and 5 mg/kg) administered piclamilast. However, piclamilast had a longer lasting effect when applied topically [22] .
Cilomilast (SB 207499, Ariflo
® ) (5)
The orally active second generation PDE4 inhibitor has been tested in several models of allergic airway diseases. It suppressed or reduced several aspects of airway inflammation in various animal models of antigen-and LTD 4 -provoked airway eosinophilia, LPS-induced pulmonary neutrophilia, and secretion of cytokines and matrix metalloproteinases into the BAL fluid (reviewed in [23] ). Phase III studies for the treatment of COPD have been encouraging and in 2003 FDA issued an approvable letter for use of cilomilast (Ariflo ® ) in maintenance of lung function in COPD patients poorly responsive to 2 -adrenoceptor agonists. Before issuing final approval, however, the FDA requested additional efficacy and safety data (arteriopathies have been observed in rats) [24, 25] . Cilomilast was also tested in models of skin inflammation and allergy. Cilomilast reduced zymosan activated plasma induced eosinophilia, but not neutrophilia in guinea pig skin [26] . Topically administered cilomilast (500 g/ear) reduced ear swelling in the chronic oxazoloneinduced contact sensitivity model (but not in the acute model) [27] , and in the Th2-dominated TDI-induced contact dermatitis [28] . The reduced inflammatory response in the TDI model was accompanied by an inhibition of several proinflammatory cytokines like, IL-1 , IL-4, IL-6, MIP-2 and chemokines like CCL-5 (RANTES) and CCL-17 (TARC) in skin tissue [29, 30] . The strong inhibitory effect was only achieved by topical administration of cilomilast (600 g/ear). Oral or intraperitoneal treatment with cilomilast (30 mg/kg) led to a weak, although significant, inhibition of the inflammatory response. The preferentially Th1-mediated DNCB-induced contact sensitivity was only marginally reduced [30] .
Cilomilast also regulated skin dendritic cell migration accompanied by a reduced MMP-9 activity in cilomilast treated skin [31] . These findings were confirmed in mice actively sensitised and challenged to TDI. After TDI challenge, the Langerhans cell (epidermal dendritic cells) density was significantly higher in cilomilast treated skin compared to vehicle treated animals. Cilomilast also inhibited LPS and IFN induced TNF and IL-12 secretion in human monocyte derived dendritic cells [32] and LPS induced TNF , IL-1 and IL-12 secretion in murine bone marrow derived dendritic cells [31, 33] . As dendritic cells are the key antigen presenting cells in allergic skin diseases these findings may add a new aspect to the immunomodulatory action of PDE4 inhibitors.
Keratinocytes seem also to be targets of PDE4 inhibition. We could demonstrate that cilomilast (0.1-10 mol/l) could dose dependently inhibit the KC secretion (mouse homologue of IL-8) from a murine keratinocyte cell line (MSC-P5) stimulated with the toll-like receptor 2 ligand peptidoglycan. Cilomilast also reduced the IFN induced IP-10 secretion in human HaCaT cells [34] .
AWD 12-281 (7)
AWD 12-281 was developed for the topical (inhalative, dermal) administration and showed strong anti-inflammatory action in several models of asthma and chronic obstructive pulmonary disease [35] . AWD 12-281 was tested in irritative and allergic dermatitis models. Topical administration reduced the arachidonic-acid-induced ear oedema in a dose dependent fashion. In the highest tested dose (5%) it was nearly equipotent to the strong cyclooxygenase inhibitor indomethacin (1%) [36] . In the TDI-induced contact dermatitis model, AWD 12-281 (600 g) inhibited the allergic inflammatory response comparable to the group III dermatocorticoid diflorasone-diacetate. Even when administered as a therapeutic intervention, AWD 12-281 reduced ear swelling and inflammatory cell influx nearly to basal levels (Fig. 3 ) [28, 29] . The reduced inflammatory response was accompanied by an inhibition of nearly all measured cytokines and chemokines in skin tissue (IL-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-17, TNF , IFN , GMCSF, G-CSF, KC, MIP-1 and RANTES) [36] . AWD 12-281 was further tested in an ovalbumin (OVA) induced allergic dermatitis model in guinea pigs. Topically administered either in acetone/DMSO or as a water-in-oil cream, AWD 12-281 reduced the allergic wheals following intradermal challenge with OVA in guinea pigs in a dose dependent fashion [36] . Based on these promising animal experiment data, a clinical phase I study was performed. Topically administered AWD 12-281 was considerably devoid of any side effects. Thus, a clinical phase II study is now under way and efficacy data are anxiously awaited (http://www.elbion.de/pipeline.html).
CC-10004
Based on the observation that thalidomide exerts effects in patients with inflammation and in specific forms of cancer, Celgene has developed a number of thalidomide derivatives aiming to improve the documented positive clinical Fig. (3) . Histological section of mouse ears. Effect of AWD 12-281 (b) on TDI induced ear swelling in mice sensitised to TDI. Compared to TDI treated control mice (a), AWD 12-281 (600 g/ear) administered 1 h after TDI challenge inhibited the inflammatory response 24 h after the challenge. Results are representative with n = 5 mice each group, scale bars: 100 m. For details see reference [29] . effects while omitting the well known severe side effects of thalidomide. Among such structural derivatives, CC-10004 (Celgene corporation) has reached clinical stages. In initial pre-clinical studies, the anti-angiogenic potential of CC-10004 was evaluated and it was found that this compound at 50 g/ml was capable of significantly down-regulating IL-6 production by human umbilical vein endothelial cells and VEGF produced by RPMI-8226 myeloma cells in cocultures in vitro [37] . The agent significantly inhibited vessel formation in the rat aortic ring assay and the chicken chorioallantoic membrane assay [10] . In additional experiments, topical CC-10004 did not alter wound healing in C57/Bl-6 mice according to tensile strength assessment and the measurement of the time to wound healing (Rosen et al., 2004 1 ). Further data indicated that the mechanism of action of CC-10004 is selective inhibition of the PDE4 enzyme, resulting in the observed inhibition of multiple cytokines. The compound was found to be a straight forward competitive inhibitor of PDE4 with an IC 50 value of about 74 nmol/l and it inhibits the LPS induced TNF release from peripheral blood mononuclear cells with an IC 50 of 110 nmol/l [10] . Therefore, the further development was directed towards the indications targeted by PDE4 inhibitors, i.e. chronic obstructive pulmonary disease, asthma, and later also psoriasis. To evaluate the potential of orally administered CC-10004 in psoriasis, SCID mice transplanted with human psoriasis plaques were utilised. Treated animals showed a 50% reduction in epidermal thickness at a dose of 5 mg/kg/day (p.o.) (Schafer, 2006 2 ) indicating potent anti-psoriasis activity. These data resemble the activity profile of PDE4 inhibitors (see [3] for review). The key problem of oral PDE4 inhibitors is the separation of pharmacological activity from side effects, headache, nausea, emesis and gastrointestinal disturbances being the most prominent ones. CC-10004 proved to be less emetogenic compared to roflumilast and cilomilast. No emesis was observed in ferrets after oral doses of up to 10 mg/kg. These data have encouraged Celgene to initiate clinical development for systemic treatment of asthma and psoriasis [10] .
RESULTS FROM CLINICAL STUDIES
The use of PDE4 inhibitors for the treatment of atopic dermatitis and psoriasis has been under discussion for decades [38] . In addition to animal studies, several clinical trials were performed to support the development of PDE4 inhibitors for treatment of inflammatory skin disorders. These studies were done in both healthy volunteers and patients with atopic dermatitis. In studies of healthy volunteers skin inflammation was introduced by administration of skin irritants, like Balsam of Peru [39] or sodium dodecyl sulphate [40] . 0.071 g/mL inhibition of PDE4 from HaCaT cells) and Ro-20-1724 (EC 50 =0.016 g/mL inhibition of PDE4 from HaCaT cells) were found to inhibit the inflammation by 69 and 57%, respectively. The study revealed a strong positive correlation between the inhibition of HaCaT keratinocyte derived PDE4 and the anti-inflammatory effect on human skin [39] .
In a study performed in the late 1970's, Ro 20-1724 was topically tested in seventeen patients with typical psoriasis plaques. Two lesions were selected on each patient and designated as site 1 and site 2. Each patient received vehicle cream and Ro 20-1724 cream (1%) in coded tube containers. Patients applied the creams (vehicle or Ro-20-1724) randomly designated for use on site 1 or site 2. The creams were applied 4 times a day for 4 weeks under occlusion. The lesions were evaluated 2, 4 and 6 weeks after the initiation of the study. Several laboratory parameters were obtained from the patients before and at the first of 2 subsequent visits. 75% of the patients showed improvements in Ro 20-1724 treated skin lesions (vs 8% in the vehicle treated lesions) at the 4 th week evaluation. None of the clinical laboratory studies revealed any abnormalities attributable to Ro 20-1724 [41] .
Ro 20-1724 (1%) was also compared to triamcinolone acetonide cream (0.025%) in 33 patients in the identical manner to the first study. There was an increase in the improvement from evaluation at 2 nd to 4 th week. The patients treated with triamcinolone improved by 84% and this improvement increased to 94% by the forth week of treatment. By contrast the percentage of improvement for Ro 20-1724 treated patients increased from 43% to 77%. In both groups, patients partially relapsed starting 2 weeks after the treatment was discontinued (6 weeks after initiation) [41] .
Cipamfylline (2)
Cipamfylline was tested in patients with a diagnosis of atopic dermatitis in a randomised, double blind, parallel group proof of concept study involving two arms in which cipamfylline was compared with vehicle and a corticosteroid [42] . 52 patients were topically treated with cipamfylline cream or its corresponding vehicle formulation and 49 patients received cipamfylline or the moderately potent corticosteroid hydrocortisone-17-butyrate (WHO class group II). Cipamfylline cream contained 1.5 mg/g cipamfylline and the steroid cream contained 0.1% hydrocortisone-17-butyrate. Cipamfylline cream, vehicle cream and hydrocortisone-17-butyrate cream were applied twice daily with a maximum application of 2 g of each per day for 14 days. The total severity score comprised of assessment of erythema, oedema/papulation, oozing/crusting, excoriations, lichenification and the overall clinical response was assessed before and after 3, 7 and 14 days of treatment. The outcome of the study revealed that cipamfylline was more effective than vehicle in treating atopic dermatitis, but less effective than a group II steroid, hydrocortisone-17-butyrate. Despite the fact that cipamfylline was topically administered detectable serum concentrations were recorded in 25% of the patients [42] . The absorption of cipamfylline and the subsequent systemic exposure might be the reason why further clinical studies with higher doses of cipamfylline have not been published.
In a further study the effect of the selective PDE4 inhibitor, cipamfylline was studied in two human models of acute and chronic irritant contact dermatitis. In the acute setting ten volunteers were patch tested at four investigation sites with sodium dodecyl sulphate (SDS, 1%) for 24 hours. For simulating a chronic damage 11 volunteers were patch tested with SDS (0.2%) 4 hours daily for four consecutive days [40] . After removing the SDS patches, the sites were topically treated with cipamfylline ointment (cipamfylline 2.5 mg/g), with ointment vehicle or with the strong corticosteroid betamethasone-17-valerate (1 mg/g cream). In the acute damage model the ointments were applied for three consecutive days, and in the repetitive model the ointments were applied for four consecutive days. Parameters being evaluated daily during treatment period were erythema and transepidermal water loss (TEWL), which is predictive of skin barrier function.
In the acute damage model neither cipamfylline nor bethasmethasone-17-valerate showed improvement in the erythema or the TEWL [40] . These results are consistent with studies by Levin et al. (2001) who also failed to show an effect of corticosteroids in an acute model of irritant contact dermatitis [43] . In the chronic model a slight reduction in erythema and TEWL was observed following treatment with betamethasone-17-valerate compared to the untreated site. In this model, the cipamfylline treated sites tended to show higher erythema and TEWL than the untreated site.
Atizoram (CP80,633) (6)
An obvious therapeutic potential of PDE4 inhibitors was confirmed in patients suffering from atopic dermatitis. In an early clinical trial, 20 patients were given the PDE4 inhibitor, atizoram for 28 days. The compound was topically applied at a concentration of 0.5% to symmetrical right and left lesions of up to 200 cm 2 . A significant improvement was observed within three days of treatment and maintained throughout the study. At day 28 of the study, 16 of the 20 treated sites showed a significant reduction in erythema, induration/papulation and excoriation compared to only 3 of the 20 placebo sites [44] .
Arofylline (1)
The efficacy of the xanthine derivate arofylline was assessed in dogs with atopic dermatitis [45] . In this study forty dogs with active atopic dermatitis and visible pruritus and skin lesions were divided into four groups (10 dogs each group): 1 mg/kg of arofylline was orally administered twice daily. As comparator, the steroid prednisone was used at a concentration of 0.5 mg/kg twice daily for the first week and 0.5 mg/kg daily for the second week. For the remaining two weeks of the study 0.5 mg/kg prednisone was administered every 48 hours. The third group received prednisone 0.25 mg/kg following the same protocol as the second group. An additional group of dogs were treated twice daily with a combination of 1 mg/kg arofylline and 0.25 mg/kg prednisone following the same protocol as in the second and third group. Concerning pruritus, arofylline was as effective as prednisone.
No significant differences were found in the rates of clinical success among the different treatment groups. This study demonstrates the therapeutic potential of PDE4 inhibitors to control the allergic symptoms of atopic dermatitis. However, it was reported that oral administration of arofylline was associated with characteristic adverse effects of PDE4 inhibitors, including nausea, vomiting and gastrointestinal disorders. Vomiting was the main reason for excluding two dogs treated with arofylline and five dogs treated with arofylline plus prednisone from the trial. Only one dog treated with prednisone alone was withdrawn from the study due to side effects [45] . Thus, this study reveals again the limitation for the use of oral PDE4 inhibitors due to systemic exposure and subsequent drug related adverse effects.
CC-10004 (8)
In phase I studies, 10 and 20 mg single and multiple doses were given daily to healthy volunteers. This treatment was well tolerated and side effects were reported to be mild [10] . No information was released with regard to the tolerability of 40 mg. In 2004, Celgene announced the initiation of phase II programs in asthma and psoriasis but to date only information on one psoriasis study has been made available. In this open label phase IIa study in patients with psoriasis the primary endpoint selected was improvement in epidermal thickness by > 20% in > 50% of the patients. Nineteen patients were enrolled and treated with 20 mg orally once daily for 29 days.
As reported recently at the Gordon Research conference (Schafer et al., 2006 3 ), the study results indicated that CC-10004 reduced the symptoms of psoriasis. While 17 patients completed the study, 15 were evaluable with regard to the primary endpoint. Eight responded with an improvement in epidermal thickness by > 20%. More than 80% of all patients showed an improvement in their psoriasis symptoms and 3 patients showed a more than 50% reduction in their PASI score. A 50% reduction is considered clinically relevant, but a 75% reduction is expected by FDA. However, the tolerability of CC-10004 was not optimal. Headache was observed in 26% of patients, nausea in 16%, dizziness in 10 and diarrhoea in 9% (Schafer et al., 2006 3 ). This side effect profile is comparable to side effects observed in longer clinical studies with other PDE4 inhibitors such as roflumilast at the highest tolerated dose [46] . To further quantify the pharmacological effect of CC-10004 and to obtain efficacy hints which may be less influenced by placebo effects, whole blood samples were taken for ex vivo lipopolysaccharide challenge to measure effect on TNF release. This method was described previously to predict systemic antiinflammatory activity [47] . While at the beginning of the study a 35.7% inhibition of TNF release was observed, the suppression reached only 16% at the end of the 29 days study. This modest effect on whole blood TNF release resembles the weak effect reported for roflumilast at the highest clinically tolerated dose [47] where the median TNF level decreased by 21% after 28 days of dosing. Taken together, these data indicate that the pharmacological effect observed in patients with psoriasis, being modest in effect, does not fully reflect the therapeutic potential of PDE4 inhibitors in this disease. Due to limited tolerability, a less than 3 Schafer, P., 2006: CC-10004: Effects of an orally available inhibitor of TNF and other inflammatory mediators in psoriasis. Gordon Research Conference Cyclic Nucleotide Phosphodiesterases, June 4-9, Biddford, ME, USA.
maximal effect was reached. Therapeutic studies aiming to increase the exposure in the target organ while improving safety are needed. Celgene is intending to progress in this direction by administering CC-10004 using a bid dosing scheme (Schafer, 2006 3 ) This indeed may result in an over all better effect since the half life of CC-10004 was reported to be only in the range of 5 hours [10] .
CONCLUSIVE REMARKS
This overview of preclinical and clinical trials with highly selective PDE4 inhibitors clearly demonstrates a sound rational for this therapeutic group with a novel, unique mode of action for the treatment of skin disorders like atopic dermatitis (Fig. 2) and psoriasis.
One general problem is the group-associated side effect profile with nausea, emesis and enhanced gastric acid production being the most critical. These side effects are dose limiting and thus the therapeutic potential of PDE4 inhibitors (see clinical studies with arofylline and CC-10004) may not be fully realised. To overcome this obstacle, the antiinflammatory action has to be discriminated from the proemetic action. The possibility of developing sub-familyselective inhibitors is one approach to solving this problem. However, this approach has considerable challenges, including the fact that different PDE4 isoforms can occur in different intrinsic conformational states leading to erroneous conclusions [3] .
A further strategy to improve the therapeutic ratio and the safety of PDE4 inhibitors for the treatment of asthma and COPD is the development of dual specificity compounds that inhibit PDE4 and PDE3, PDE5 or PDE7 [48] . However, to date, no data are obtainable concerning efficacy and safety profile of dual-specificity PDE inhibitors for the treatment of skin disorders.
A more promising approach is to utilise the topical route of administration. A PDE4 inhibitor that is optimised for the topical route could have a potent and long-lasting local effect and results in only minimal systemic exposure. The topical PDE4 inhibitor, AWD 12-281 (GW842470; elbion AG & Glaxo Smith Kline) that is currently in clinical phase II trials for the treatment of atopic dermatitis (homepage elbion AG; www.elbion/pipeline.html) combines these characteristics and is an interesting drug candidate for therapy of atopic dermatitis.
However, only the outcome of longer term clinical trials will bring full knowledge of the therapeutic value of PDE4 inhibitors for the treatment of atopic dermatitis and psoriasis.
